Harnessing real-world evidence to reduce the burden of noncommunicable disease: health information technology and innovation to generate insights.
Data science
Disease burden
Health information technology
Noncommunicable disease
Population health
Real-world data
Real-world evidence
Risk factors
Journal
Health services & outcomes research methodology
ISSN: 1387-3741
Titre abrégé: Health Serv Outcomes Res Methodol
Pays: Netherlands
ID NLM: 9815809
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
05
2020
revised:
01
09
2020
accepted:
09
10
2020
pubmed:
12
11
2020
medline:
12
11
2020
entrez:
11
11
2020
Statut:
ppublish
Résumé
Noncommunicable diseases (NCDs) are the leading causes of mortality and morbidity across the world and factors influencing global poverty and slowing economic development. We summarize how the potential power of real-world data (RWD) and real-world evidence (RWE) can be harnessed to help address the disease burden of NCDs at global, national, regional and local levels. RWE is essential to understand the epidemiology of NCDs, quantify NCD burdens, assist with the early detection of vulnerable populations at high risk of NCDs by identifying the most influential risk factors, and evaluate the effectiveness and cost-benefits of treatments, programs, and public policies for NCDs. To realize the potential power of RWD and RWE, challenges related to data integration, access, interoperability, standardization of analytical methods, quality control, security, privacy protection, and ethical standards for data use must be addressed. Finally, partnerships between academic centers, governments, pharmaceutical companies, and other stakeholders aimed at improving the utilization of RWE can have a substantial beneficial impact in preventing and managing NCDs.
Identifiants
pubmed: 33173407
doi: 10.1007/s10742-020-00223-7
pii: 223
pmc: PMC7646714
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8-20Informations de copyright
© Springer Science+Business Media, LLC, part of Springer Nature 2020.
Références
Lancet. 2015 Aug 22;386(9995):743-800
pubmed: 26063472
Eur Heart J. 2020 Jan 1;41(1):12-85
pubmed: 31820000
Eur J Hum Genet. 2020 May;28(5):609-626
pubmed: 31844175
N Engl J Med. 2020 Feb 13;382(7):674-678
pubmed: 32053307
Curr Oncol. 2019 Nov;26(Suppl 1):S53-S56
pubmed: 31819710
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
Lancet. 2016 Oct 8;388(10053):1659-1724
pubmed: 27733284
Lancet Glob Health. 2015 Dec;3(12):e746-57
pubmed: 26497599
Glob Public Health. 2017 Apr;12(4):396-415
pubmed: 26948138
JAMA Cardiol. 2020 Jul 1;5(7):743-744
pubmed: 32211809
Int J Evid Based Healthc. 2018 Sep;16(3):154-166
pubmed: 29608458
Diabetes Res Clin Pract. 2020 Jun;164:108215
pubmed: 32416122
Arthritis Care Res (Hoboken). 2014 Dec;66(12):1790-8
pubmed: 24905637
Trials. 2015 Nov 03;16:495
pubmed: 26530985
J Multidiscip Healthc. 2018 Jul 02;11:295-304
pubmed: 29997436
J Multidiscip Healthc. 2020 Jul 22;13:671-679
pubmed: 32801731
Stud Health Technol Inform. 2015;216:574-8
pubmed: 26262116
Med Care. 2017 Mar;55(3):244-251
pubmed: 27787351
Value Health. 2008 Jan-Feb;11(1):44-7
pubmed: 18237359
Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1201-1212
pubmed: 31823482
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
PLoS One. 2018 Nov 1;13(11):e0206702
pubmed: 30383802
BMJ Open. 2018 Jan 21;8(1):e016982
pubmed: 29358417
Am J Prev Med. 2005 Dec;29(5 Suppl 1):4-10
pubmed: 16389119
BMC Cardiovasc Disord. 2019 Mar 15;19(1):62
pubmed: 30876393
Heart Asia. 2019 Sep 2;11(2):e011176
pubmed: 31565075
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
BMJ. 2019 Jan 28;364:l251
pubmed: 30692093
Mayo Clin Proc. 2011 Apr;86(4):304-14
pubmed: 21389250
N Engl J Med. 2016 Dec 8;375(23):2293-2297
pubmed: 27959688